Michael S. Cuffe - 30 Jan 2023 Form 4 Insider Report for HCA Healthcare, Inc. (HCA)

Role
EVP and Chief Clinical Officer
Signature
/s/ Kevin A. Ball, Attorney-in-Fact
Issuer symbol
HCA
Transactions as of
30 Jan 2023
Transactions value $
-$1,028,440
Form type
4
Filing time
01 Feb 2023, 18:57:10 UTC
Previous filing
23 Feb 2022
Next filing
22 Feb 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction HCA Common Stock Gift $0 -450 -1.78% $0.00 24.8K 31 Oct 2022 Direct F1
transaction HCA Common Stock Sale -$1.03M -4K -16.11% $257.11 20.8K 01 Feb 2023 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction HCA Stock Appreciation Right Award $0 +14.5K $0.00 14.5K 30 Jan 2023 Common Stock 14.5K $253.30 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 2,330.5543 shares acquired under the HCA Holdings, Inc. Employee Stock Purchase Plan.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $257.1031 to $257.285, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The stock appreciation rights vest in four equal annual installments beginning on January 30, 2024.